IDYA News and Press, IDEAYA Biosciences Inc.

2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...

2024-07-10 05:31:27 ET More on related stocks Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer? Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality' Aehr Test Systems: The Bottom Might Be In IDEAYA Biosciences stock slides after ...

2024-07-10 03:07:59 ET More on IDEAYA Biosciences Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer? Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality' IDEAYA announces proposed public offering of common stock and pre-funded warrants ...

2024-07-09 13:42:27 ET More on Tango Therapeutics Seeking Alpha’s Quant Rating on Tango Therapeutics Historical earnings data for Tango Therapeutics Financial information for Tango Therapeutics Read the full article on Seeking Alpha For further...

2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...

2024-07-08 14:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for IDYA on July 8, 2024 12:43PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $40.01 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-07-08 13:17:27 ET More on IDEAYA Biosciences Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer? Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality' Ideaya stock jumps after positive study data from cancer study Seeking Alpha...

2024-07-08 10:35:18 ET Summary Ideaya Biosciences is a cancer-focused biotech with promising pipeline candidates darovasertib and IDE397 targeting uveal melanoma and MTAP-deleted cancers. Darovasertib has shown strong results in phase 2 trials for uveal melanoma, while IDE397 demo...

2024-07-08 07:58:27 ET Ideaya Biosciences ( NASDAQ: IDYA ) shares jumped as much as 23% premarket on Monday after the oncology company reported positive interim data from an expansion dose cohort of a mid-stage trial of IDE397.... Read the full article on Seeking Alpha...